Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CFD | P00746 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10911245 | 0.90 | TRPV1 (0.47) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL6718744 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL11400920 | 0.80 | ALDH1A1 (0.49) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL11400542 | 0.80 | ALDH1A1 (0.49) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL7252945 | 0.77 | ITGB3 (0.48) | HSD17B10SMN1; SMN2FFAR4PTPN1RAB9A | |
| SCHEMBL9776114 | 0.74 | SMN1; SMN2 (0.47) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL9776124 | 0.74 | SMN1; SMN2 (0.47) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL22033119 | 0.73 | BLM (0.56) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL2331138 | 0.73 | ALDH1A1 (0.53) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL13929122 | 0.73 | AKT1 (0.56) | ALDH1A1KDM4EPOLBCFDTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | ALDH1A1 100/4885KDM4E 1203/4885HPGD 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.